|
gptkbp:instanceOf
|
gptkb:antibiotic
gptkb:drug
|
|
gptkbp:administeredBy
|
oral
intramuscular injection
|
|
gptkbp:ATCCode
|
J04AC01
|
|
gptkbp:brand
|
gptkb:Laniazid
gptkb:Nydrazid
|
|
gptkbp:CASNumber
|
54-85-3
|
|
gptkbp:chemicalFormula
|
C6H7N3O
|
|
gptkbp:contraindication
|
acute liver disease
previous isoniazid-induced hepatitis
|
|
gptkbp:discoveredBy
|
gptkb:Jörgen_Lehmann
|
|
gptkbp:discoveredIn
|
1951
|
|
gptkbp:drugClass
|
hydrazide
|
|
gptkbp:eliminationHalfLife
|
1–4 hours
|
|
gptkbp:introducedIn
|
1952
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits mycolic acid synthesis
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
137.14 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
|
|
gptkbp:sideEffect
|
gptkb:peripheral_neuropathy
fever
rash
hepatotoxicity
|
|
gptkbp:synonym
|
isonicotinic acid hydrazide
|
|
gptkbp:usedFor
|
tuberculosis
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:rifampicin
gptkb:Mycobacterium_bovis
gptkb:Mycobacterium_tuberculosis_subsp._tuberculosis
gptkb:Sir_John_Crofton_method
gptkb:phenytoin
gptkb:rifampin
gptkb:FabI
gptkb:Dilantin
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
isoniazid
|